Nolin TD - Search Results

1

Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease.

Prokopienko AJ, Nolin TD. Prokopienko AJ, et al. Among authors: nolin td. Expert Rev Clin Pharmacol. 2018 Jan;11(1):71-82. doi: 10.1080/17512433.2018.1378095. Epub 2017 Sep 20. Expert Rev Clin Pharmacol. 2018. PMID: 28905671 Free PMC article. Review.

2

Nonrenal drug clearance in CKD: Searching for the path less traveled.

Momper JD, Venkataramanan R, Nolin TD. Momper JD, et al. Among authors: nolin td. Adv Chronic Kidney Dis. 2010 Sep;17(5):384-91. doi: 10.1053/j.ackd.2010.05.009. Adv Chronic Kidney Dis. 2010. PMID: 20727508 Review.

3

Optimizing drug development and use in patients with kidney disease.

Nolin TD, Arya V, Sitar DS, Pfister M. Nolin TD, et al. J Clin Pharmacol. 2011 May;51(5):628-30. doi: 10.1177/0091270011402500. J Clin Pharmacol. 2011. PMID: 21525394 No abstract available.

4

Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.

Tortorici MA, Cutler DL, Hazra A, Nolin TD, Rowland-Yeo K, Venkatakrishnan K. Tortorici MA, et al. Among authors: nolin td. J Clin Pharmacol. 2015 Mar;55(3):241-50. doi: 10.1002/jcph.444. Epub 2015 Jan 14. J Clin Pharmacol. 2015. PMID: 25501531 Review.

5

Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5.

Yoshida K, Sun B, Zhang L, Zhao P, Abernethy DR, Nolin TD, Rostami-Hodjegan A, Zineh I, Huang SM. Yoshida K, et al. Among authors: nolin td. Clin Pharmacol Ther. 2016 Jul;100(1):75-87. doi: 10.1002/cpt.337. Epub 2016 Mar 7. Clin Pharmacol Ther. 2016. PMID: 26800425 Free PMC article.

6

Implications of Kidney Disease on Metabolic Reduction.

Alshogran OY, Nolin TD. Alshogran OY, et al. Among authors: nolin td. Curr Drug Metab. 2016;17(7):663-72. doi: 10.2174/1389200217666160603131320. Curr Drug Metab. 2016. PMID: 27262337 Review.

7

Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP.

Tan ML, Yoshida K, Zhao P, Zhang L, Nolin TD, Piquette-Miller M, Galetin A, Huang SM. Tan ML, et al. Among authors: nolin td. Clin Pharmacol Ther. 2018 May;103(5):854-867. doi: 10.1002/cpt.807. Epub 2017 Oct 9. Clin Pharmacol Ther. 2018. PMID: 28990182 Free PMC article.

8

Decreased Kidney Function Is Associated with Enhanced Hepatic Flavin Monooxygenase Activity and Increased Circulating Trimethylamine N-Oxide Concentrations in Mice.

Johnson C, Prokopienko AJ, West RE 3rd, Nolin TD, Stubbs JR. Johnson C, et al. Among authors: nolin td. Drug Metab Dispos. 2018 Sep;46(9):1304-1309. doi: 10.1124/dmd.118.081646. Epub 2018 Jun 18. Drug Metab Dispos. 2018. PMID: 29915157

9

Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates.

Tan ML, Zhao P, Zhang L, Ho YF, Varma MVS, Neuhoff S, Nolin TD, Galetin A, Huang SM. Tan ML, et al. Among authors: nolin td. Clin Pharmacol Ther. 2019 Mar;105(3):719-729. doi: 10.1002/cpt.1205. Epub 2018 Oct 26. Clin Pharmacol Ther. 2019. PMID: 30074626 Free PMC article.

10

Trimethylamine N-Oxide and Cardiovascular Outcomes in Patients with ESKD Receiving Maintenance Hemodialysis.

Stubbs JR, Stedman MR, Liu S, Long J, Franchetti Y, West RE 3rd, Prokopienko AJ, Mahnken JD, Chertow GM, Nolin TD. Stubbs JR, et al. Among authors: nolin td. Clin J Am Soc Nephrol. 2019 Feb 7;14(2):261-267. doi: 10.2215/CJN.06190518. Epub 2019 Jan 21. Clin J Am Soc Nephrol. 2019. PMID: 30665924 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

161 results

Search Page

Filters